Understand the story, not the spin.
Recent Verilumia coverage about Moderna, Inc. (MRNA), including reporting-tone insights and market listing information.
The Democratic Republic of Congo has begun the Tumaini clinical trial in Bunia to assess whether an existing Ebola vaccine can protect against the Bundibugyo virus responsible for the country’s outbreak, the World...
Merck and Moderna said a personalized mRNA vaccine added to pembrolizumab reduced the risk of melanoma recurrence or death by 42% in a phase III trial involving 1,137 patients whose high-risk tumors had been...
Moderna shares plunged on October 22 after late-stage results for its personalized melanoma vaccine, developed with Merck, became public, even as the companies reported reduced risks of recurrence and cancer spread....
Moderna and Merck said a personalized mRNA vaccine, added to Keytruda after surgery for high-risk melanoma, reduced the relative risk of recurrence or death by 42% over the first two years in a Phase 3 trial...
Verilumia 
